Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16697597 | 1.00 | ADORA3 (0.82) | ADORA3LMNATDP1ALDH1A1MAPT | |
| SCHEMBL16698091 | 0.88 | ADORA3 (0.81) | ADORA3LMNATDP1ALDH1A1MAPT | |
| SCHEMBL16698094 | 0.88 | ADORA3 (0.81) | ADORA3LMNATDP1ALDH1A1MAPT | |
| SCHEMBL16697599 | 0.83 | MAPT (0.58) | ADORA3LMNATDP1ALDH1A1MAPT | |
| SCHEMBL16697866 | 0.82 | ADORA3 (0.80) | ADORA3LMNATDP1ALDH1A1MAPT | |
| SCHEMBL16697869 | 0.82 | ADORA3 (0.80) | ADORA3LMNATDP1ALDH1A1MAPT | |
| SCHEMBL16698083 | 0.77 | MAPT (0.62) | ADORA3LMNATDP1ALDH1A1MAPT | |
| SCHEMBL16698080 | 0.77 | MAPT (0.62) | ADORA3LMNATDP1ALDH1A1MAPT | |
| SCHEMBL16698037 | 0.77 | ADORA3 (0.71) | ADORA3LMNATDP1ALDH1A1MAPT | |
| SCHEMBL16698040 | 0.77 | ADORA3 (0.71) | ADORA3LMNATDP1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133495-A1 | Substituted Acyloxyamidines as HCV NS3/4A Inhibitors | VIROCURA THERAPEUTICS INC (CA) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133495-A1 | Substituted Acyloxyamidines as HCV NS3/4A Inhibitors | EIF2AK2, GTF3C4, GTF3C1 | ADORA3 2615/4885LMNA 4687/4885TDP1 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.